Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Medicure · Myocardial Infarction · Acute Coronary Syndromes
Phase 2
Completed
535
2021-05
Industry sponsor intelligence
MedicureClinical Pipeline.
Lead-sponsor view of Medicure's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 1
- Avg enrollment
- 268
Pipeline overview
Programs by phase and activity.
Velocity
Medicure trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 21
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Bivalirudin → | 1 | 0 | 0 | 1 | 0 | 0 |
| Eptifibatide → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Medicure studies.
This page groups studies where Medicure is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first